IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing. IRX Therapeutics also announced that John D. Halpern and George P. Denny III have joined its Board of Directors, expanding the Board to nine members. Mr. Halpern and Mr...
More...
More...